Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Amyris to Get Up to $60 Million in Temasek Funding for Biofuels

Don't Miss Out —
Follow us on:

Aug. 8 (Bloomberg) -- Amyris Inc., the biotechnology company part-owned by Total SA, will sell as much as $60 million in convertible notes to Temasek Holdings Pte.

Temasek will buy $35 million of notes in an initial tranche and later may purchase an additional $25 million of notes, Emeryville, California-based Amyris said today in a statement. The first tranche is expected to close next month. The second may be issued at the company’s discretion within two years of the agreement, depending on meeting certain milestones at a Brazil production site.

Amyris reported a second-quarter net loss of $38.9 million, or 51 cents a share, compared with $46.8 million, or 81 cents, from a year earlier, according to a statement today. Five analysts surveyed by Bloomberg had estimated a quarterly loss of 43 cents a share.

Amyris uses genetically modified microorganisms to convert plant-sugars into farnesene, a hydrocarbon that can be processed into fuels or specialty chemicals. Total, France’s largest oil producer, owns 18 percent of the company, according to data compiled by Bloomberg. Temasek is the second-largest shareholder.

To contact the reporter on this story: Justin Doom in New York at jdoom1@bloomberg.net

To contact the editor responsible for this story: Reed Landberg at landberg@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.